We are excited to announce the approval of Eteplirsen (now renamed Exondys 51), the first drug that treats the underlying cause of Duchenne. Read article here.

To wait over a year for this FDA approval was excruciating, but many of us in the community have been working hard for this outcome for over a decade. When we funded the Dusty Brandom Fellowship in Steve Wilton's lab starting in 2005, oligos and exon skipping were a dream that we felt needed to be realized.

Congratulations Sarepta on realizing that dream. We now look forward to a class of drugs addressing other exons on the dystrophin gene that will treat a large proportion of boys and young men with Duchenne - men like my son Dusty Brandom who is now 23. 

Thank you for all your support throughout the years. We are really making a difference together.